A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-11-03
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-16 (study day 32); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 35); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 55); relationship: not assessed
Data queries
No data queries.